Redeye shares its preview of OssDsign’s Q4 2023e results, due on February 6.
Redeye provides its initial take on Scandion Oncology communicating phase IIa CORIST part 3 top-line...
All-share bid valued at ~SEK 1.85bn (44% premium) Aros and Besqab are fairly equal in size (mcap, on...
Sales +1.1% and adj. EBIT SEK -0.4m vs. ABGSCe CF worse than expected due to NWCC, balance now SEK 9...
Adj. EBITA SEK 289m (-3% vs. ABGSCe 299m) Consensus EBITA should not change much 10x 2024e EBITA on ...
With the fresh 10-year deal to supply Lidl from a new 10,000 sqm production facility in a FaaS-setup...
Ossur reported strong growth and weak margins in Q4 New Medicare reimbursement could have substantia...
We expect Suominen to continue improving its profitability in Q4, driven by lower raw material price...
Q-linea has announced a SEK 50m OPEX reduction ahead of the announced CEO change in 2024.
Inför Q4-rapporten räknar Analysguiden med omsättningstillväxt.
Redeye leaves a comment following Alzinova’s announcement of a completed primary analysis of the pha...
Stark Q4 cementerar återgång till pre-pandeminivåer Inför Q4 hade vi förväntningar på starkt momentu...
SRV will release its Q4 results on Feb 1; we expect revenue to turn to growth with ongoing business ...
Redeye updates on EG7 ahead of its Q4-results (due 13 February) where we expect a stable year-end pe...
Ahead of NoHo's Q4 report, due on 15 February, we adjust our estimates to reflect the guidance updat...
Redeye has a positive take on today’s news that Alzecure has advanced ACD137 as a drug candidate as ...
We cut '23e-'25e adj. EBITA by 13-10% Inflation data for Q4 suggest negative-to-neutral volume/mix T...
Our estimates for net sales and EBIT are slightly above consensus for Q4.
Q4e: Tuesday, 30 January at 8:00 CET Healthy 2024 with 6% organic growth and solid margin expansion ...
Redeye updates its estimates after Ependion’s Q4 2023 report, which was slightly weaker than our est...
.jpg)
